RENALYTIX AI PLC LS-,0025
RENALYTIX AI PLC LS-,0025
Acción · GB00BYWL4Y04 · A2N765 (XLON)
Resumen Indicadores financieros
0,07 GBP
-1,17 % -0,0008 GBP
Precio de cierre XLON 06.06.2025: 7,17 GBX
London (XLON) · Precios actuales y gráficos en MoneyPeak
06.06.2025 14:10

Cotizaciones actuales de RENALYTIX AI PLC LS-,0025

BolsaTickerMonedaÚltima operaciónPrecioVariación diaria
XLON: London
London
RENX.L
GBX
06.06.2025 14:10
7,17 GBX
7,32 GBX
-2,12 %

Rendimiento

Día Semana Mes 3 meses 6 meses 1 año 5 años
0,00 % -10,44 % -10,55 % -22,12 % -9,87 % -56,58 % -98,41 %

Perfil de la empresa para RENALYTIX AI PLC LS-,0025 Acción

Renalytix Plc develops artificial intelligence-enabled in vitro diagnostic solutions for kidney diseases. The company offers KidneyIntelX, a diagnostic platform that employs an artificial intelligence-enabled algorithm that combines various data inputs, including validated blood-based biomarkers, inherited genetics and personalized patient data from electronic health record systems to generate a unique patient risk score. Its products are used in kidney disease diagnosis and prognosis, clinical care, patient stratification for drug clinical trials, and drug target discovery. Renalytix AI plc has a license agreement with Mount Sinai Health System to develop and commercialize licensed products in connection with the application of artificial intelligence for the diagnosis of kidney disease; Joslin Diabetes Center, Inc. for developing and commercializing products for diagnosing and predicting kidney disease using biomarkers; and Kantaro Biosciences LLC for developing and commercializing laboratory tests for the detection of antibodies against SARS-CoV-2. The company also has a partnership agreement with Atrium Health, Wake Forest Baptist Health, and Wake Forest School of Medicine to implement an advanced clinical care model designed to improve kidney health and reduce kidney disease progression and kidney failure in high-risk populations. The company was formerly known as Renalytix AI plc and changed its name to Renalytix Plc in June 2021. Renalytix Plc was incorporated in 2018 and is headquartered in New York, New York.

Fondos invertidos

Los siguientes fondos han invertido en: RENALYTIX AI PLC LS-,0025 invertido:

Fondo
iShares MSCI UK Small Cap UCITS ETF GBP (Acc)
Vol. en millones
593,21
Porcentaje (%)
0,10 %

Datos de la empresa

Nombre RENALYTIX AI PLC LS-,0025
Empresa Renalytix Plc
Sitio web https://renalytix.com
Mercado principal XLON London
WKN A2N765
ISIN GB00BYWL4Y04
Tipo de valor Acción
Sector Healthcare
Industria Medical - Healthcare Information Services
CEO Mr. James R. McCullough M.B.A.
Capitalización de mercado 26 Mio
País Estados Unidos de América
Moneda GBP
Empleados 0,1 T
Dirección 1460 Broadway, 10036 New York
Fecha de OPV 2018-11-06

Símbolos de cotización

Nombre Símbolo
Frankfurt 2O9.F
London RENX.L

Otras acciones

Los inversores que tienen RENALYTIX AI PLC LS-,0025 también tienen las siguientes acciones en su cartera:
DZ BANK CLN E.8924
DZ BANK CLN E.8924 Bono
LBBW AD FESTZINS 21/27
LBBW AD FESTZINS 21/27 Bono
La plataforma financiera MoneyPeak rastrea y analiza inversiones y carteras. Desde depósitos de valores hasta compras de criptomonedas.
Útil, simple y gratuito. Acciones, ETF, ETC, ETN, índices, fondos, bonos, certificados, divisas, opciones, derechos de suscripción.
Aviso legal Protección de datos Blog Comunidad Comentarios Changelog
Im App Store herunterladen Bei Google Play herunterladen
Todos los derechos reservados © LCP GmbH 2025